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Abstract
Background: Performance status, a predictor of cancer survival, and ability to maintain independent living deteriorate in advanced 
disease. Understanding predictors of performance status trajectory could help identify those at risk of functional deterioration, target 
support for independent living and reduce service costs. The relationship between symptoms, analgesics and performance status is 
poorly delineated.
Aim: The aim of this study is to determine whether demographics, analgesics, disease characteristics, quality-of-life domains and 
C-reactive protein predict the trajectory of Karnofsky Performance Status (KPS) in patients with advanced cancer.
Design: The study design is the secondary data analysis of the international prospective, longitudinal European Palliative Care Cancer 
Symptom study (ClinicalTrials.gov: NCT01362816). A multivariable regression model was built for KPS area under the curve per day 
(AUC).
Setting and participants: This included adults with advanced, incurable cancer receiving palliative care, without severe cognitive 
impairment and who were not imminently dying (n = 1739).
Results: The mean daily KPS AUC (n = 1052) was 41.1 (standard deviation = 14.1). Opioids (p < 0.001), co-analgesics (p = 0.023), poorer 
physical functioning (p < 0.001) and appetite loss (p = 0.009) at baseline were explanatory factors for lower KPS AUC. A subgroup 
analysis of participants with C-reactive protein data (n = 240) showed that only C-reactive protein (p = 0.040) and physical function 
(p < 0.001) were associated with lower KPS AUC.
Conclusion: This study is novel in determining explanatory factors for subsequent functional trajectories in an international dataset and 
identifying systemic inflammation as a candidate therapeutic target to improve functional performance. The effect of interventions 
targeting physical function, appetite and inflammation, such as those used for cachexia management, on maintaining functional 
status in patients with advanced cancer needs to be investigated.
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Original Article
What is already known about the topic?
•• Performance status and ability to maintain independent living deteriorate in advanced disease and are associated with 
cancer survival.
•• Palliative care interventions may help support independent living and reduce health and social care costs.
•• The relationships between symptoms, analgesics and performance status are poorly delineated.
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Introduction
Performance status is an independent predictor of cancer 
survival.1–5 It is often impaired in patients with advanced 
disease.4 Performing activities of daily living is an impor-
tant patient priority; minimising burden on others was 
‘very important’ for 89% patients.6 Symptoms negatively 
impact function.7,8 Pain is associated with decreased 
Karnofsky Performance Status (KPS).9 Better symptom 
management could improve performance status. 
However, longitudinal data exploring the association 
between symptoms, analgesics and performance status 
are limited. Understanding predictors of performance sta-
tus could help identify those at risk of deterioration, so 
palliative interventions can be planned.10,11 If such inter-
ventions help maintain function sufficient for independent 
community-based living, health and social care costs could 
be reduced.12 KPS is a measure of overall function (includ-
ing impact of psychosocial factors), allowing patients to be 
classified according to their functional impairment.13 
C-reactive protein (CRP), as a marker of inflammation, has 
been associated with poorer performance.14
Aim
The aim of this study is to explore whether demographics, 
analgesics, disease characteristics and the palliative care 
version of the European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire–Core15 
(EORTC QLQ-C15-PAL) items at baseline predict KPS tra-
jectory in patients with advanced cancer and the effect of 
CRP on these relationships. Our null hypothesis is that 
there is no relationship between these variables and per-
formance status over time.
Methods
Study design
The study design is the secondary data analysis of the pro-
spective, longitudinal, multi-site European Palliative Care 
Cancer Symptom study (ClinicalTrials.gov: NCT01362816), 
which recruited from April 2011 to October 2013.15 
Detailed study methods have been published.15 Eligible 
participants were consenting adults (⩾18 years) with 
advanced, incurable cancer receiving palliative care, not 
imminently dying and scoring ⩾4/8 on the four-item 
Mini–Mental State Examination. Data registration con-
sisted of registration of patients’ medical data by health-
care providers, and patient self-reported data on key 
sociodemographic items: age, sex and living situation and 
questions about common cancer-related symptoms, qual-
ity of life and functional status. Assessments were per-
formed upon study inclusion and monthly ±1-week 
follow-up, either at hospital or by mailed postal question-
naires, for at least 6 months if possible.15
In total, the dataset included 1739 patients. The base-
line characteristics have been published previously.15 This 
analysis uses the full dataset, and records with occasional 
missing values for single variables were retained. Table 1 
shows data collected at each visit.
Statistical analyses
The characteristics of the patients are presented for the 
baseline assessment using mean and standard deviation 
(SD), minimum and maximum, or n (%).
The dependent outcome measure was area under the 
curve (AUC) for performance status using KPS. All serial 
measurements of KPS were plotted against time. AUC 
from entry to the study to death (KPS of zero assigned) 
was calculated using the trapezoid rule.17 The summary 
score for KPS was expressed as the total area under the 
KPS curve from study entry until death, divided by the 
total number of days represented (KPS AUC per day), 
thereby reflecting average but not actual daily scores.
To compare mean KPS AUC per day and categorical 
variables (sex, location, cancer stage and analgesics), two-
tailed Student’s t-tests or analysis of variance (ANOVA) 
tests were used. Pearson’s correlations were used for age 
and the EORTC QLQ-C15-PAL scales and items. Candidate 
What this paper adds?
•• Opioids, co-analgesics, poorer physical functioning and appetite loss at baseline were associated with a lower Karnofsky 
Performance Status over time.
•• In a subgroup analysis which included C-reactive protein, only this and physical function were associated with a lower 
Karnofsky Performance Status over time.
•• This study identifies systemic inflammation as a candidate therapeutic target to improve functional performance.
Implications for practice, theory or policy
•• A thorough assessment of clinical and patient-reported data is needed to identify and subsequently manage issues 
potentially leading to a deteriorating performance status.
•• The effect of interventions to improve physical function, appetite and inflammation, such as those used for cachexia 
management, on maintaining functional status in patients with advanced cancer needs to be investigated.
•• Further research assessing this association and the impact of managing systemic inflammation on clinical outcomes is needed.
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predictors were chosen if there was a plausible biological 
and knowledge-based rationale between cause and out-
come (e.g. have a relationship between cause and out-
come based on existing knowledge). Univariable and 
multivariable regression models were used to explore fur-
ther the relationships between KPS AUC per day with 
β (standard error (SE)), as well as the p-value for each pre-
dictor presented. Candidate predictors associated at the 
p < 0.2 level at univariable analysis, and/or with a plausi-
ble biological rationale, were included in the multivariable 
model in this exploratory analysis. A subgroup analysis of 
participants with CRP data (n = 240) was performed. All 
analyses were undertaken on STATA SE (StataCorp 2015, 
Stata Statistical Software: Release14; StataCorp LP, College 
Station, TX).
Ethical approval
Ethical approval was obtained at each European 
Palliative Care Cancer Symptom study recruiting site. 
The Regional Research Ethics Committee in Medicine, 
Central Norway, evaluated and accepted the project on 
26 November 2010. The study was performed according 
to the Declaration of Helsinki. No further ethical 




At baseline, 1739 patients were included (65.8 years (SD 
= 12.4 years), range = 21–97 years; men 50%). Baseline 
characteristics are shown in Table 2. At baseline, the mean 
KPS score was available for 1724 patients. The mean KPS 
score at baseline was 67.0 (16.5), and 719 (42%) had a 
performance status <70%. The last recorded KPS values 
showed a mean KPS of 62.8 (18.2) and 895/1730 (52%) 
had performance status below 70%.
During the study, 1090 patients died (25 with no docu-
mented date of death). The characteristics of these 
patients are shown in Table 2. AUC was calculated for 
1052 patients, where baseline KPS was recorded. The 
mean KPS AUC per day was 41.1 (14.1) and data were nor-
mally distributed. Mean KPS AUC per day was lower for 
those with baseline KPS <70% (33.3 (11.9)) than those 
scoring ⩾70% (49.0 (11.6), p < 0.001). Similarly, mean 
KPS AUC per day at their last study visit was lower for 
those with KPS <70% (36.5 (13.0)) than those scor-
ing ⩾70% (49.0 (12.3), p < 0.001).
Table 3 shows a univariable analysis of baseline charac-
teristics and mean (SD) KPS AUC per day. Increasing age 
was associated with lower KPS AUC per day (r = −0.153, 
p < 0.01). The mean KPS AUC per day was lower for those 
who were an inpatient and used any opioid, non-opioid 
analgesic and co-analgesic at baseline. However, higher 
mean KPS AUC per day was seen in those with metastatic/
disseminated disease at baseline compared to local/
locally advanced.
Table 4 shows the correlations between EORTC QLQ-
C15-PAL items and KPS AUC per day; the strongest corre-
lation was for physical functioning (r = 0.539). Except 
nausea/vomiting, more severe symptoms were correlated 
with lower KPS AUC per day.
Table 5 shows the univariable and multivariable analy-
ses. Older age (p = 0.004), opioids (p < 0.001), co-analge-
sics (p = 0.023), lower levels of physical functioning 
(p < 0.001) and more severe appetite loss (p = 0.009) at 
baseline remained as independent explanatory factors for 
reduced KPS AUC over time. Together these factors 
explained 34.8% (R2 of final model) of the relationship, 
indicating that other variables are important.
Table 1. Data collected at each assessment visit.
Collected by healthcare providers Self-reported patient measures
•• Patient location: inpatient, day care/outpatient, home
•• Karnofsky Performance Status (KPS): 0%–100%; 100 is 
‘perfect’ health and 0 is dead
•• Analgesic use (yes/no), for non-opioid analgesics, 
opioids and co-analgesics
{{ Co-analgesics were defined as drugs that are not 
designed to manage pain per se, but which has 
effects that can help reduce the pain, for example, 
antidepressants and anticonvulsants
{{ Non-opioid analgesics included paracetamol and 
non-steroidal anti-inflammatory drugs.
•• C-reactive protein (CRP)
The palliative care version of the European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire–15 (EORTC 
QLQ-C15-PAL).16 Item scored from 1 ‘not at all’ to 4 ‘very much’ and was 
transformed to a 0–100 scale
•• Functional items: high score means a good function or quality of life
{{ Physical functioning
{{ Emotional functioning
{{ Global quality of life
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CRP subgroup analysis
In the subgroup analysis, the baseline characteristics of 
participants with CRP data (n = 240) are shown in Table 2. 
These patients were slightly older and there was a higher 
proportion male, with metastatic/disseminated disease, 
inpatient and lower KPS, compared to the whole sample. 
Only CRP and physical function were associated with 
change in KPS: lower physical functioning (β (SE) = 0.15 
(0.04), p < 0.001) and CRP (β (SE) = −0.03 (0.01), 
p = 0.040). Opioids (p = 0.114), co-analgesics (p = 0.187) 
and severe appetite loss (p = 0.078) were not significant. 
The R2 value of this model was 34.0%.
Discussion
Summary of main findings
These data indicate that older age (β (SE) = −0.09 (0.32), 
p = 0.004); opioids use (β (SE) = −3.63 (0.89), p < 0.001); 
co-analgesics use (β (SE) = −2.04 (0.90), p = 0.023); poorer 
physical function, where a high score means a good physi-
cal function (β (SE) = 0.19 (0.03), p < 0.001); and appe-
tite loss at baseline, where a high score indicates more 
severe symptoms (β (SE) = −0.03 (0.01), p = 0.009) were 
independent predictors of worse KPS over time in patients 
with advanced cancer. A CRP subgroup analysis showed 
Table 2. Descriptive characteristics at baseline.
Total
Mean (SD), min–max, n (%)
Patients with CRP at baseline
Mean (SD), min–max, n (%)
Patients who died
Mean (SD), min–max, n (%)
Age (years) 65.8 (12.4), 21–97 67.3 (12.1) 66.6 (12.5), 23–97
n = 1739 n = 240 n = 1052
Sex Female 871 (50%) 101 (42%) 478 (45%)
  Male 866 (50%) 139 (58%) 574 (55%)
  Missing 2 0 0
Stage Metastatic/
disseminated
1437 (84%) 219 (91%) 887 (84%)
  Local/locally 
advanced
284 (16%) 21 (9%) 163 (16%)
  Missing 18 0 2
Location of care Inpatient 365 (21%) 105 (44%) 275 (27%)
  Day care 1026 (61%) 92 (38%) 595 (58%)
  Home 300 (18%) 36 (15%) 154 (15%)
  Missing 48 7 28
Non-opioid 
analgesics
Yes 808 (47%) 103 (43%) 552 (53%)
  No 896 (53%) 134 (57%) 486 (47%)
  Missing 35 3 14
Opioids Yes 1012 (59%) 136 (58%) 677 (65%)
  No 694 (41%) 99 (42%) 361 (35%)
  Missing 33 5 14
Co-analgesics Yes 410 (24%) 41 (17%) 257 (25%)
  No 1279 (76%) 194 (83%) 768 (75%)
  Missing 50 5 27
CRP 55.0 (77.7), 0–379, n = 240 55.0 (77.7), 0–379, n = 240 65.8 (77.9), 1–379, n = 185
KPS 67.0 (16.5), 10–100, n = 1724 63.9 (18.7), 20–100, n = 239 63.8 (16.2), 10–100, n = 1052
EORTC QLQ-C15-PAL
 Physical functioning 64.8 (29.2), 0–100, n = 1698 56.1 (30.5), 0–100, n = 232 59.7 (29.6), 0–100, n = 1021
 Emotional functioning 68.7 (23.9), 0–100, n = 1695 70.3 (26.2), 0–100, n = 232 69.5 (24.0), 0–100, n = 1019
 Global quality of life 51.5 (26.3), 0–100, n = 1682 48.4 (27.2), 0–100, n = 229 49.5 (26.1), 0–100, n = 1009
 Fatigue 50.0 (28.7), 0–100, n = 1700 53.6 (31.4), 0–100, n = 232 52.2 (28.6), 0–100, n = 1022
 Nausea/vomiting 17.4 (27.4), 0–100, n = 1699 21.3 (29.6), 0–100, n = 232 18.6 (28.0), 0–100, n = 1021
 Pain 38.3 (31.1), 0–100, n = 1700 43.6 (34.2), 0–100, n = 232 40.9 (31.5), 0–100, n = 1022
 Dyspnoea 23.3 (28.9), 0–100, n = 1694 28.1 (31.0), 0–100, n = 231 26.7 (30.8), 0–100, n = 1018
 Sleep disturbances 31.3 (28.9), 0–100, n = 1693 34.2 (33.8), 0–100, n = 231 30.8 (32.3), 0–100, n = 1019
 Appetite loss 33.8 (34.8), 0–100, n = 1698 42.0 (37.3), 0–100, n = 232 36.8 (35.3), 0–100, n = 1021
 Constipation 27.5 (31.8), 0–100, n = 1688 32.5 (34.7), 0–100, n = 228 30.0 (33.3), 0–100, n = 1012
SD: standard deviation; CRP: C-reactive protein; KPS: Karnofsky Performance Status; EORTC QLQ-C15-PAL: The Palliative Care version of the Euro-
pean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire.
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that this inflammatory marker was statistically significant 
at explaining worse performance. In this model, only CRP 
and physical function remained significantly associated 
with deteriorating KPS. In both models, two-thirds of the 
variability was unexplained. KPS incorporates a much 
broader construct than physical function alone, also con-
sisting of mental and behavioural approaches and social 
support.
The only statistically significant symptom remaining in 
the final model in the whole dataset was loss of appetite. 
This is consistent with the findings of the CRP sub-analy-
sis. In a Japanese secondary data analysis, increased CRP 
was associated with more physician-rated symptoms 
(fatigue, anorexia and weight loss dyspnoea) and poorer 
activities of daily living were observed in advanced cancer 
patients receiving palliative care.14 Although this study 
primarily looked for associations with KPS, there are 
similarities in the findings, notably the association of CRP 
with cancer-cachexia symptoms and ability to perform 
everyday tasks. Inflammation could act as a uniting patho-
physiological process for analgesics, poorer physical func-
tion and loss of appetite. Inflammatory cancers are more 
painful.18,19 Inflammatory cytokines mediate cancer 
cachexia with accompanying anorexia and loss of skeletal 
muscle mass with reduction in physical function and 
worse prognosis.20,21 Inflammation leading to fatigue 
decreases exercise capacity and movement, exacerbating 
skeletal muscle loss.22 There is a need to detect cancer-
related cachexia early, and have a multimodal approach, 
to maintain function for as long as possible.23
Implications for practice
This study was an exploratory analysis to indicate patients 
at risk of deterioration in performance status, and targets 
for intervention to ameliorate this decline. These data 
suggest that attention to the inflammatory state with 
accompanying anorexia cachexia, including regular weight 
measurement and appetite assessment and nutritional 
status, is important in this context.
Limitations
This was a large European prospective cohort study; as it 
was an observational study, only associations (not causa-
tion) can be determined. Although consecutive patients 
were recruited, those with cognitive impairment were 
excluded. Some of the statistical associations had small 
effect sizes and are unlikely to be clinically relevant, as 
reported in a previous study.8 Pro-inflammatory cytokines, 
acute infections and acute medical conditions influence 
CRP levels. The associations found in the subgroup analy-
sis need to be examined in a larger group.
Table 3. Karnofsky Performance Status area under the curve per day by baseline characteristics.
Baseline characteristics Mean (SD) N p-Value
Sex Female 41.4 (13.6) 478 0.434
Male 40.8 (14.6) 574
Stage Local/locally advanced 38.9 (13.1) 163 0.036
Metastatic/disseminated 41.5 (14.3) 887
Location of care Inpatient 33.4 (12.9) 275 <0.001
Day care 46.0 (12.4) 595
Home 35.9 (14.6) 154
Non-opioid analgesics Yes 41.1 (13.5) 552 0.045
No 41.3 (14.8) 486
Opioids Yes 38.9 (13.4) 677 <0.001
No 45.4 (14.6) 361
Co-analgesics Yes 39.1 (12.9) 257 0.004
No 42.0 (14.5) 768
SD: standard deviation.
The total number of participants included for each characteristic is variable due to missing data.
p-Values that reached statistical significance are in bold.
Table 4. Correlations between EORTC QLQ-C15-PAL items and 
Karnofsky Performance Status area under the curve per day.
EORTC QLQ-C15-PAL Correlation N p-Value
Physical functioning 0.539 1021 <0.001
Emotional functioning 0.216 1019 <0.001
Global quality of life 0.242 1009 <0.001
Fatigue −0.315 1022 <0.001
Nausea/vomiting −0.031 1021 0.326
Pain −0.209 1022 <0.001
Dyspnoea −0.151 1018 <0.001
Sleep disturbances −0.076 1019 0.015
Appetite loss −0.255 1021 <0.001
Constipation −0.177 1012 <0.001
EORTC QLQ-C15-PAL: The Palliative Care version of the European 
Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire.
p-Values that reached significance are in bold.
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Conclusion
This secondary data analysis of the European Palliative Care 
Cancer Symptom study data set of adults with advanced, 
incurable cancer showed an association of lower average 
daily KPS with opioids, co-analgesics, lower levels of physi-
cal functioning at baseline and appetite loss. A CRP sub-
analysis indicated that systemic inflammation has a role in 
performance status and may be a useful therapeutic target 
to help patients maintain function. Interventions targeting 
physical function, appetite and inflammation, such as those 
used for cachexia management, may help maintain KPS in 
people with advanced cancer. Further research assessing 
this association and the impact of managing systemic 
inflammation on clinical outcomes is needed.
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